About Abeomics
Founded in 2013, Abeomics develops research reagents, engineered cell lines and assay platforms for life science research. The company combines expertise in immunology, cell biology and recombinant protein technologies to support studies of cellular signalling, immune regulation and disease mechanisms. Its platforms include reporter and stable cell lines, recombinant monoclonal antibodies, biosimilar antibodies and cell-based assay systems. These tools enable researchers to investigate pathway activity, evaluate biological responses and characterise therapeutic targets. Abeomics supports applications in immunology, cancer research, infectious diseases, stem cell biology, apoptosis, DNA repair and drug discovery.
Abeomics offers a portfolio of antibodies, recombinant proteins, ligands, inhibitors, immune checkpoint reagents and assay kits for molecular and cellular research workflows. Product families include recmAb™ recombinant antibodies, sdMAB™ single-domain antibodies, reporter cell lines and luciferase-based assay platforms. The company also provides custom services for stable cell line development, protein production, recombinant antibody generation and compound screening. These capabilities support target validation, pathway analysis, high-throughput screening and early-stage therapeutic research.
Europa Biosite’s subsidiaries distribute for Abeomics in Belgium, Canada, Denmark, Estonia, Finland, Germany, Iceland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden and the United States of America.